Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

White Paper: New horizons to drive the future of Medicine

07.06.2013
The European Technology Platform on Nanomedicine (ETPN) and the NANOMED2020 project announce the publication of the White Paper on Contribution of Nanomedicine to Horizon 2020, the next European Framework Programme for Research and Innovation till 2020.

This strategic document provides a set of key recommendations for the European Commission and the EU Member States to create a favourable ecosystem for the successful deployment of Nanomedicine in Europe. It lays thereby the groundwork to manage the efficient translation of nanotechnology from a Key Enabling Technology (KET) into new and innovative medical products.

Nanomedicine, also defined as the use of nanotechnologies in medicine, supports a strong research and emerging industrial healthcare sector in Europe. Based on excellent academic research and innovative SMEs, nanomedicine has the potential to answer today’s societal challenges such as the ageing population. ETPN’s White Paper will actively contribute to shaping the three pillars of “Horizon 2020 – Excellence in Science, Industrial Leadership and Societal Challenges”.

Based on an in-depth analysis of the main bottlenecks in the translation of nanomedicine to the market, i.e. the inefficient selection process of translatable projects and the lack of technical infrastructures, such as pharmacology and toxicology facilities, the White Paper strives for the creation of an strong SME based supply chain for innovative therapeutics and diagnostics as a profitable industrial sector. This will support innovation, competitiveness and keep production and high tech jobs in Europe for the benefit of both the European economy and European patients.

The pivotal proposition of the White Paper is the establishment of a Nanomedicine Translation Hub designed as an umbrella for a set of complementary actions and initiatives such as:

• a dedicated Nanomedicine Translation Advisory Board (TAB) with experienced industrial experts to select, guide and push forward the best translatable concepts,
• an European Nano-Characterisation Laboratory (EU-NCL) for physical, chemical and biological characterisation of nanomaterials intended for medical use,
• GMP manufacturing pilot lines for clinical batches to assist both academia and SMEs to develop nanomedical materials for validation in clinical trials, before transfer to dedicated manufacturing organisations,

• a dedicated NanoMed SME instrument aiming at funding discovery projects and innovative SMEs in order to keep excellence in nanomedicine research and more importantly develop products.

Nano-concepts for a macro-impact on EU economy

The implementation of these recommendations in Horizon 2020 represents a unique opportunity for Europe to foster innovation in healthcare and to push for the emergence of a leading nanomedicine sector. With an estimated total budget of 800 Mio €, it will therefore actively contribute to the re-localisation of pharmaceutical research and to the re-industrialisation of Europe, being thereby a significant factor for growth and for job creation. With nearly 250 “nano”-products used or tested in humans worldwide, representing about 10% of pharma sales and a $130.9 billion market by 2016, nanomedicine is meant to have a real impact on the European economy.

The European Commission has the potential to play a major role in this process through its framework programme Horizon 2020. In coordination with Member States and by funding the research of cutting-edge technologies for the future of Medicine, by de-risking innovation in SMEs and by facilitating the dialogue with regulatory authorities and large industrial partners, the European Commission can actively support the nanomedical sector for the benefit of the patients.

The White Paper “Contribution of Nanomedicine to Horizon 2020” is available for download on the ETP Nanomedicine website under http://www.etp-nanomedicine.eu/etpn-white-paper-2013

About the ETP Nanomedicine

The ETP Nanomedicine has been established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. With more than 120 active members from industry, academia, healthcare providers and public authorities, the ETPN coordinates joint research efforts together with its members, the European Commission and the EU Member States. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe and contributed to set up numerous EU funded projects providing thus a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicines.

About NANOMED2020

NANOMED2020 is a Coordination and Support Action under the FP7-Health aiming at delivering concrete recommendations to the European Commission to push forward the field of nanomedicine under Horizon 2020. Amongst other activities, NANOMED2020 is focusing on

• federating the nanomedicine community and establishing a European landscape via mapping all relevant actors, projects and infrastructures and

• identifying the key bottlenecks of the value chain to focus on to leverage the translational possibilities of the development process and to bring in the end more products onto the market.

This project involves seven partners across Europe including the ETPN Secretariat, the CLINAM foundation (Switzerland), the National Institute of Health Carlos III (Spain), Bioanalytik-muenster e.V (Germany), Nanobiotix SA (France), the Fondazione Don Carlo Gnocchi ONLUS (Italy), and SINTEF (Norway).

Contact
Mr. Nicolas Gouze
Head of ETP Nanomedicine Secretariat / NANOMED2020 coordinator
c/o VDI/VDE Innovation + Technik GmbH
nicolas.gouze@vdivde-it.de
http://www.etp-nanomedicine.eu

Wiebke Ehret | idw
Further information:
http://www.etp-nanomedicine.eu
http://www.etp-nanomedicine.eu/etpn-white-paper-2013

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>